EGFR and non-small cell lung carcinoma: On 24 October 2016, the FDA expanded its approval as the first-line treatment for metastatic non-small-cell lung cancer with high PDL-1 expression (≥ 50%) but no EGFR or ALK mutation (Category 1 and preferred; category 2B if PDL-1 1–49%).